STOCK TITAN

Twist Bioscience Corporation (TWST) Financials

TWST NASDAQ
FY2026 annual
Revenue $459.4M +22.0% YoY
Net Income -$130.2M n/m YoY
EPS (Diluted) -$2.08 n/m YoY
Free Cash Flow -$89.0M n/m YoY
Market Cap $7.0B as of Nov 20, 2026
Price / Sales 15.3x on $459.4M revenue, FY2026
Price / Earnings n/m net loss, so no earnings multiple, FY2026
Price / Book 7.9x on $888.0M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Sep 30, 2026 Reported Currency USD FYE September

Newest figures come from the 10-K for FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TWST SEC filings page.

Twist Bioscience Corporation (TWST) reported $459.4M in revenue for fiscal year 2026, up 22.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TWST FY2026

Revenue growth is improving gross margins, but persistent operating losses and external financing still define how this business operates.

From FY2024 to FY2026, gross margin rose 9.8 percentage points, yet FY2026 net margin was -28.3%; improved unit economics still did not cover the operating structure. In FY2026, operating cash flow was -$41.4M against a net loss of $130.2M, indicating cash absorption was materially smaller than the accounting loss.

The FY2025-to-FY2026 net margin movement was a deterioration of 7.7 percentage points even as gross margin improved 1.7 percentage points. That divergence indicates overhead and other below-gross-profit costs absorbed the latest improvement in product-level profitability.

FY2026 financing cash flow was $446.7M, while liabilities represented 20.8% of assets. This points to a balance sheet supported more by financing inflows than internally generated cash, with a modest liability load relative to assets.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 52 / 100
Financial Health Score 52/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Twist Bioscience Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
22

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Twist Bioscience Corporation scores 22/100 on it among other operating companies.

Growth
82

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Twist Bioscience Corporation scores 82/100 on it among other operating companies.

Leverage
76

Twist Bioscience Corporation carried $0.26 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2026. With no long-term debt figure for fiscal year 2026, Twist Bioscience Corporation is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 76/100 among other operating companies measured the same way.

Liquidity
93

Twist Bioscience Corporation held $5.86 of current assets for every $1 of current liabilities at the end of fiscal year 2026, a current ratio of 5.86. Liquidity ranks operating companies on that ratio, and Twist Bioscience Corporation scores 93/100 among other operating companies.

Cash Flow
9

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Twist Bioscience Corporation scores 9/100 on it among other operating companies.

Returns
28

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Twist Bioscience Corporation scores 28/100 on it among other operating companies.

Altman Z-Score Safe
16.92

Twist Bioscience Corporation scores 16.92, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $7.0B against total liabilities of $233.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/8

Twist Bioscience Corporation passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Twist Bioscience Corporation reported a net loss of $130.2M while operations used $41.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$126.6M
YoY+27.9%
QoQ+7.0%
5Y CAGR+27.3%

Twist Bioscience Corporation generated $126.6M in revenue in Q4 2026. This represents an increase of 27.9% from the same quarter a year earlier. Against the prior quarter it is up 7.0%.

EBITDA
-$17.3M
YoYn/m
QoQn/m
5Y CAGRn/m

Twist Bioscience Corporation's EBITDA was -$17.3M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$20.6M
YoYn/m
QoQn/m
5Y CAGRn/m

Twist Bioscience Corporation reported a net loss of $20.6M in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.30
YoYn/m
QoQn/m
5Y CAGRn/m

Twist Bioscience Corporation earned -$0.30 per diluted share (EPS) in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$20.1M
YoYn/m
QoQn/m
5Y CAGRn/m

Twist Bioscience Corporation recorded an outflow of $20.1M in free cash flow in Q4 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$534.0M
YoY+191.7%
QoQ+354.7%
5Y CAGR+2.8%

Twist Bioscience Corporation held $534.0M in cash as of Q4 2026; no long-term debt figure is on record for that period.

Shares Outstanding
68M
YoY+11.5%
QoQ+8.7%
5Y CAGR+6.6%

Twist Bioscience Corporation had 68M shares outstanding in Q4 2026. This represents an increase of 11.5% from the same quarter a year earlier. Against the prior quarter it is up 8.7%.

Dividends Per Share

Not reported for Q4 2026.

Margins & Returns

Gross Margin
53.1%
YoY+1.8pp
QoQ+0.3pp
5Y change+12.4pp

Twist Bioscience Corporation's gross margin was 53.1% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.

Operating Margin
-19.3%
YoY+11.0pp
QoQ+11.4pp

Twist Bioscience Corporation's operating margin was -19.3% in Q4 2026, reflecting core business profitability. This is up 11.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.4 percentage points.

Net Margin
-16.3%
YoY+11.1pp
QoQ+13.3pp

Twist Bioscience Corporation's net profit margin was -16.3% in Q4 2026, showing the share of revenue converted to profit. This is up 11.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.3 percentage points.

Return on Equity
-2.3%
YoY+3.4pp
QoQ+5.5pp
5Y change+4.8pp

Twist Bioscience Corporation's quarterly ROE was -2.3% in Q4 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.5 percentage points.

Capital Allocation

R&D Spending
$17.0M
YoY-0.2%
QoQ-5.8%
5Y CAGR-2.7%

Twist Bioscience Corporation invested $17.0M in research and development in Q4 2026. This represents a decrease of 0.2% from the same quarter a year earlier. Against the prior quarter it is down 5.8%.

Capital Expenditures
$20.0M
YoY+60.6%
QoQ+104.4%
5Y CAGR+19.8%

Twist Bioscience Corporation invested $20.0M in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 60.6% from the same quarter a year earlier. Against the prior quarter it is up 104.4%.

Share Buybacks

Not reported for Q4 2026.

TWST Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TWST quarterly income statement
MetricQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-Q/A
Revenue$126.6M+27.9%$118.4M+23.2%$110.7M+19.3%$103.7M+16.9%$99.0M+16.9%$96.1M+17.9%$92.8M+23.2%$88.7M+24.1%
Cost of Revenue$59.4M+23.3%$55.9M+24.9%$53.6M+14.6%$49.7M+8.4%$48.2M+3.6%$44.8M-3.1%$46.8M+5.3%$45.9M+7.8%
Gross Profit$67.3M+32.3%$62.5M+21.7%$57.1M+24.1%$54.0M+26.0%$50.8M+33.0%$51.3M+45.4%$46.0M+49.0%$42.8M+47.9%
R&D Expenses$17.0M-0.2%$18.0M-0.1%$19.7M-17.7%$17.1M-19.6%$17.0M-19.5%$18.0M-19.7%$23.9M-1.0%$21.3M-7.8%
SG&A Expenses$74.7M+17.1%$80.7M+27.4%$76.1M+19.5%$69.7M+24.1%$63.8M+20.0%$63.4M+11.6%$63.7M+14.5%$56.2M+6.3%
Operating Income-$24.4Mn/m-$36.3Mn/m-$45.9Mn/m-$32.9Mn/m-$29.9Mn/m-$30.1Mn/m-$41.6Mn/m-$34.6Mn/m
EBITDA-$17.3Mn/m-$29.5Mn/m-$39.4Mn/m-$26.7Mn/m-$23.9Mn/m-$24.1Mn/m-$35.2Mn/m-$28.3Mn/m
Interest ExpenseN/AN/AN/AN/AN/AN/A$143Kn/m$24Kn/m
Income Tax-$201K-178.5%$311K+62.8%$43K-75.4%$253K+160.8%$256Kn/m$191K0.0%$175K-49.3%$97K-19.2%
Net Income-$20.6Mn/m-$35.1M-271.9%-$44.0Mn/m-$30.5Mn/m-$27.1Mn/m$20.4Mn/m-$39.3Mn/m-$31.6Mn/m
EPS (Basic)-$0.30n/m-$0.56-264.7%-$0.71n/m-$0.50n/m-$0.45n/m$0.34n/m-$0.66n/m-$0.53n/m
EPS (Diluted)-$0.30n/m-$0.56-269.7%-$0.71n/m-$0.50n/m-$0.45n/m$0.33n/m-$0.66n/m-$0.53n/m
Diluted Shares (Avg)N/A62M+2.0%62M+3.4%61M+3.2%N/A61M+5.2%60M+3.2%59M+2.9%

TWST Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TWST quarterly balance sheet
MetricQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-Q
Total Assets$1.1B+74.8%$672.4M+4.5%$676.2M+13.5%$638.1M+4.8%$641.9M+4.5%$643.6M+0.9%$595.6M-15.3%$608.6M-17.0%
Current Assets$737.2M+121.4%$321.3M-5.4%$323.4M-4.4%$303.9M-12.0%$333.0M-4.0%$339.8M-6.1%$338.4M-9.0%$345.3M-11.5%
Cash & Equivalents$534.0M+191.7%$117.4M-41.7%$122.7M-41.7%$148.6M-32.9%$183.0M-19.1%$201.4M-15.8%$210.4M-13.5%$221.4M-16.8%
Short-Term Investments$47.9M-3.0%$49.4M0.0%$49.0M+4.9%$49.4M-0.1%$49.4M-1.4%$49.4M-1.7%$46.7M-6.6%$49.4M+10.1%
Inventory$46.4M+63.9%$35.2M+35.6%$33.5M+60.7%$32.9M+40.0%$28.3M+17.6%$25.9M-8.9%$20.9M-31.3%$23.5M-23.8%
Accounts Receivable$70.2M+23.1%$65.1M+30.5%$64.2M+28.4%$50.1M+27.3%$57.0M+63.4%$49.9M+55.9%$49.9M+38.8%$39.3M+11.2%
Goodwill$82.2M0.0%$82.2M0.0%$82.2M-4.2%$82.2M-4.2%$82.2M-4.2%$82.2M-4.2%$85.8M0.0%$85.8M0.0%
Total Liabilities$233.8M+38.4%$226.7M+37.1%$221.1M+42.2%$182.0M+19.2%$168.9M+19.3%$165.4M+12.5%$155.5M+9.0%$152.6M+6.9%
Current Liabilities$125.8M+37.6%$120.3M+38.1%$120.0M+60.0%$80.4M+15.5%$91.4M+28.7%$87.1M+18.0%$75.0M+11.1%$69.6M+6.8%
Non-Current Liabilities$108.0M+39.3%$106.4M+35.9%$101.1M+25.6%$101.5M+22.4%$77.5M+9.7%$78.3M+7.0%$80.5M+7.1%$83.0M+7.0%
Total Equity$888.0M+87.8%$445.7M-6.8%$455.1M+3.4%$456.1M0.0%$473.0M+0.1%$478.2M-2.6%$440.1M-21.4%$455.9M-22.7%
Retained Earnings-$1.4Bn/m-$1.4Bn/m-$1.4Bn/m-$1.4Bn/m-$1.3Bn/m-$1.3Bn/m-$1.3Bn/m-$1.3Bn/m

Not reported in any period shown, so not listed: Long-Term Investments, Long-Term Debt.

TWST Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TWST quarterly cash flow statement
MetricQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-Q/A
Operating Cash Flow-$173Kn/m$1.1Mn/m-$17.6Mn/m-$24.8Mn/m-$11.8Mn/m-$1.4Mn/m-$13.0Mn/m-$21.4Mn/m
Depreciation & Amortization$7.1M+18.2%$6.8M+11.8%$6.4M+0.2%$6.2M-2.9%$6.0M-9.8%$6.1M-26.9%$6.4M-22.9%$6.4M-21.9%
Stock-Based CompensationN/A$18.2M+13.2%$18.9M-6.8%$13.3M+10.7%N/A$16.1M+16.9%$20.3M+47.0%$12.0M+8.8%
Capital Expenditures$20.0M+60.6%$9.8M+6.5%$7.9M+90.3%$10.0M+339.8%$12.4M+520.7%$9.2M+849.7%$4.1M+587.2%$2.3M+50.6%
Free Cash Flow-$20.1Mn/m-$8.6Mn/m-$25.4Mn/m-$34.8Mn/m-$24.2Mn/m-$10.6Mn/m-$17.1Mn/m-$23.7Mn/m
Investing Cash Flow-$20.3Mn/m-$10.2Mn/m-$12.7Mn/m-$9.9Mn/m-$12.4Mn/m-$9.4Mn/m-$1.4Mn/m-$1.5M-136.9%
Financing Cash Flow$438.5M+7766.1%$3.8M+107.4%$4.1M+29.5%$298K-98.3%$5.6M+53.7%$1.8M-37.2%$3.2M+74.8%$17.9Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TWST Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TWST quarterly financial ratios
MetricQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-Q/A
Gross Margin53.1%+1.8pp52.8%-0.6pp51.6%+2.0pp52.0%+3.8pp51.3%+6.2pp53.4%+10.1pp49.6%+8.6pp48.3%+7.8pp
Operating Margin-19.3%+11.0pp-30.6%+0.7pp-41.4%+3.4pp-31.7%+7.3pp-30.2%+12.3pp-31.4%-44.8%+20.1pp-39.1%+26.7pp
Net Margin-16.3%+11.1pp-29.6%-50.8pp-39.8%+2.6pp-29.4%+6.2pp-27.4%+13.5pp21.2%-42.4%+18.0pp-35.6%+24.5pp
Return on Equity-2.3%+3.4pp-7.9%-12.1pp-9.7%-0.7pp-6.7%+0.2pp-5.7%+1.6pp4.3%+21.7pp-8.9%-0.8pp-6.9%+0.4pp
Return on Assets-1.8%+2.4pp-5.2%-8.4pp-6.5%+0.1pp-4.8%+0.4pp-4.2%+1.4pp3.2%+16.6pp-6.6%-0.1pp-5.2%+0.7pp
Current Ratio5.86+2.2x2.67-1.2x2.70-1.8x3.78-1.2x3.64-1.2x3.90-1.0x4.51-1.0x4.96-1.0x
Liabilities-to-Equity0.26-0.1x0.51+0.2x0.49+0.1x0.40+0.1x0.36+0.1x0.350.0x0.35+0.1x0.33+0.1x
Asset Turnover0.110.0x0.180.0x0.160.0x0.160.0x0.150.0x0.150.0x0.160.0x0.150.0x
FCF Margin-15.9%+8.6pp-7.3%+3.7pp-23.0%-4.5pp-33.6%-6.8pp-24.5%-4.0pp-11.0%-2.0pp-18.5%+8.1pp-26.7%+7.5pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Twist Bioscience Corporation TWST FY2026 $459.4M -$130.2M -28.3% $7.0B 52/100
Caris Life Sciences, Inc. CAI FY2025 $812.0M -$68.1M -8.4% $5.0B 55/100
Axsome Therapeutics, Inc AXSM FY2025 $638.5M -$183.2M -28.7% $6.8B 34/100
Kodiak Sciences Inc KOD FY2025 N/A -$230.0M N/A $6.4B —
Oruka Therapeutics, Inc. ORKA FY2025 N/A -$105.4M N/A $6.5B —
Immunovant, Inc. IMVT FY2026 N/A -$505.6M N/A $6.6B —

Frequently Asked Questions

Twist Bioscience Corporation (TWST) reported $459.4M in total revenue for fiscal year 2026. This represents a 22.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Twist Bioscience Corporation (TWST) revenue grew by 22.0% year-over-year, from $376.6M to $459.4M in fiscal year 2026.

No, Twist Bioscience Corporation (TWST) reported a net loss of $130.2M in fiscal year 2026, with a net profit margin of -28.3%.

Twist Bioscience Corporation (TWST) reported diluted earnings per share of -$2.08 for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Twist Bioscience Corporation (TWST) had EBITDA of -$113.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

Twist Bioscience Corporation (TWST) had a gross margin of 52.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

Twist Bioscience Corporation (TWST) had an operating margin of -30.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

Twist Bioscience Corporation (TWST) had a net profit margin of -28.3% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Twist Bioscience Corporation (TWST) has a return on equity of -14.7% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

Twist Bioscience Corporation (TWST) recorded an outflow of $89.0M in free cash flow during fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Twist Bioscience Corporation (TWST) recorded an outflow of $41.4M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

Twist Bioscience Corporation (TWST) had $1.1B in total assets as of fiscal year 2026, including both current and long-term assets.

Twist Bioscience Corporation (TWST) invested $47.6M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

Twist Bioscience Corporation (TWST) invested $71.8M in research and development during fiscal year 2026.

Twist Bioscience Corporation (TWST) had 68M shares outstanding as of fiscal year 2026.

Twist Bioscience Corporation (TWST) had a current ratio of 5.86 as of fiscal year 2026, which is generally considered healthy.

Twist Bioscience Corporation (TWST) had a liabilities-to-equity ratio of 0.26 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.

Twist Bioscience Corporation (TWST) had a return on assets of -11.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

Twist Bioscience Corporation (TWST) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $7.0B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Twist Bioscience Corporation (TWST) trades at 15.3x sales, its market capitalization divided by $459.4M revenue, FY2026. The market capitalization is $7.0B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Twist Bioscience Corporation (TWST) has an Altman Z-Score of 16.92, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Twist Bioscience Corporation (TWST) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Twist Bioscience Corporation (TWST) reported a net loss of $130.2M while operations used $41.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Twist Bioscience Corporation (TWST) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top